Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
Clinical trial NCT05623319 · RECRUITING
Trial details
- NCT number
- NCT05623319
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-27
- Primary completion
- 2027-07-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.